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Background
In sub-Saharan Africa, over 1,300,000 pregnant women 
were living with HIV in 2007, 73,000 of which were in the 
small southern country, Malawi, landlocked between 
Tanzania, Zambia, and Mozambique, just North of 
Zimbabwe [1]. More than 300,000 children were newly 
infected with HIV in 2007, predominantly through 
mother-to-child transmission (HIV MTCT) [2]. Much of 
the risk of HIV MTCT can be reduced by treatment with 
single dose nevirapine (NVP). However, in many areas, 
mothers and their infants do not receive such regimens, 
and even in the context of prophylactic treatment, some 
infants become infected whereas others remain free of 
infection. Furthermore, HIV transmission can occur 
during pregnancy, labor and delivery, or through breast-
feeding, by mechanisms which remain to be elucidated.
Th   ere is evidence for genetic variability in the mother 
and/or infant to be associated with susceptibility to HIV 
MTCT. However, a larger wealth of research describes 
genetic associations with adult HIV transmission and 
progression to AIDS. Th  e following paragraphs note 
pertinent ﬁ  ndings for various modes of HIV transmission 
and disease progression.
Abstract
Background: More than 300,000 children are newly infected with HIV each year, predominantly through mother-
to-child transmission (HIV MTCT). Identifi  cation of host genetic traits associated with transmission may more clearly 
explain the mechanisms of HIV MTCT and further the development of a vaccine to protect infants from infection. 
Associations between transmission and a selection of genes or single nucleotide polymorphisms (SNP)s may give an 
incomplete picture of HIV MTCT etiology. Thus, this study employed a genome-wide association approach to identify 
novel variants associated with HIV MTCT.
Methods: We conducted a nested case-control study of HIV MTCT using infants of HIV(+) mothers, drawn from a 
cohort study of malaria and HIV in pregnancy in Blantyre, Malawi. Whole genome scans (650,000 SNPs genotyped 
using Illumina genotyping assays) were obtained for each infant. Logistic regression was used to evaluate the 
association between each SNP and HIV MTCT.
Results: Genotype results were available for 100 HIV(+) infants (at birth, 6, or 12 weeks) and 126 HIV(-) infants (at birth, 
6, and 12 weeks). We identifi  ed 9 SNPs within 6 genes with a P-value <5 × 10-5 associated with the risk of transmission, 
in either unadjusted or adjusted by maternal HIV viral load analyses. Carriers of the rs8069770 variant allele were 
associated with a lower risk of HIV MTCT (odds ratio = 0.27, 95% confi  dence interval = 0.14, 0.51), where rs8069770 is 
located within HS3ST3A1, a gene involved in heparan sulfate biosynthesis. Interesting associations for SNPs located 
within or near genes involved in pregnancy and development, innate immunological response, or HIV protein 
interactions were also observed.
Conclusions: This study used a genome-wide approach to identify novel variants associated with the risk of HIV 
MTCT in order to gain new insights into HIV MTCT etiology. Replication of this work using a larger sample size will help 
us to diff  erentiate true positive fi  ndings.
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medium, provided the original work is properly cited.Alteration of viral entry has been implicated for several 
genes. One mechanism of cell entry involves HIV-1 
binding with the CD4 receptor and co-receptor 
chemokine (CC motif) receptor 5 (CCR5). Th   e CCR5 co-
receptor also binds with chemokines produced by CD8+ 
T cells, including RANTES (CCL5), and MIP (macro-
phage inﬂ  ammatory protein) 1α (CCL3) and 1β (CCL4). 
Higher concentrations of these ligands have been 
associated with a lower risk of HIV-1 infection and 
progression to AIDS, likely through competition with R5 
strains of HIV for binding with the CCR5 receptor, 
preventing HIV from entering the cell and replicating 
[3-8]. Genes that regulate ligands for chemokine receptor 
genes have been associated with the risk of HIV infection, 
a notable example existing for chemokine (C-C motif) 
ligand 3-like 1 (CCL3L1). CCL3L1 copy number lower 
than population average has been associated with an 
increased risk of HIV transmission through diﬀ  erent 
modes of transmission (adult and perinatal) and across 
various ethnic groups [9-13]. CCL3L1  copy number 
varia  tion has also been associated with HIV/AIDS 
progression in adults [10,14-16].
Genes regulating  co-receptor availability are also 
involved in HIV susceptibility. A prominent example in 
adults is the 32-base-pair deletion in the open reading 
frame of the CCR5 gene (CCR5-Δ32), where individuals 
homozygous for the Δ32 mutation are nearly resistant to 
infection by R5 strains [5-7,17,18]. However, the mutation 
does not always signiﬁ   cantly alter susceptibility to 
maternal infection among infants [19]. Th  e rarity of the 
Δ32 mutation in African populations [20], where HIV 
MTCT is more common, may account for this lack of 
association. It is possible that other CCR5 variations, such 
as the promoter polymorphisms 2459 (59029 or 
rs1799987) and 2135 (59353 or rs1799988), play stronger 
roles for HIV MTCT, when taking maternal HIV viral load 
into account [21]. CCR5-2132 (59356) has been noted for 
an increased risk of death among HIV-infected women, 
although the same study did not observe associations 
between CCR5 polymorphisms 2135 (59353), 2086 (59402 
or rs1800023), and 2459 (59029 or rs1799987) and HIV 
MTCT [22].
Depending on the viral strain [23], HIV can use the CXC 
chemokine receptor 4 (CXCR4) as a co-receptor for CD4 
for cell entry. Like CCR5, CXCR4 can be blocked by 
endogenous ligands [24,25]. Th   e natural ligand for CXCR4 
is the stromal cell-derived factor 1 (SDF1) [26-28], 
encoded by SDF1 ( CXCL12).  SDF1-3-prime-A has been 
associated with a reduced risk of HIV-1 infection [24,25], 
but not necessarily progression to AIDS [29,30] or HIV 
MTCT in African or other ancestry groups [31,32].
Intermediary receptors on dendritic or endothelial cells 
can be used by HIV-1 [33,34], and altered susceptibility 
to infection may result from polymorphisms in the genes 
regulating such receptors. Th  is includes Dendritic cell-
speciﬁ  c ICAM-grabbing non-integrin (DC-SIGN) [35-38] 
and syndecan genes such as SDC-2 [39]. High levels of 
DC-SIGN mRNA in the human placenta suggests a role 
for DC-SIGN for in utero transmission of HIV, even in 
the context of low maternal viral load [34]. Syndecans 
may be less important alone as they are when connected 
with other factors such as chemokine receptors or 
heparan sulfate. For example, the SDC-4/CXCR4 
complex binds with SDF-1 [40], which can alter HIV 
binding. Th  e syndecan protein bound with heparan 
sulfate (proteoglycan) can also bind with gp120 of HIV-1 
[41], which may facilitate HIV-1 cell entry [42] or cell-
free transport [43]. Th  ere are multiple genes encoding 
syndecans and heparan sulfate proteglycans that remain 
to be clearly described in relation to HIV MTCT.
Finally, genes involved in the host immune response 
can play a role in HIV/AIDS susceptibility. Th   e valine to 
isoleucine substitution at codon 64 in the chemokine co-
receptor 2b gene (CCR2-V64I) demonstrates linkage 
disequilibrium with the CCR5 promoter region [44] and 
is common in populations of African ancestry [44-46]. 
Th  e natural ligand of CCR2  is CCL2 (MCP-1), which 
does not bind with CCR5 or CXCR4 [47]. CCR2- V64I is 
associated with delayed disease progression in adults, but 
with variable replication [44,48-50]. It is possible that the 
CCR2 gene does not individually inﬂ  uence  HIV 
progression to AIDS, but rather, acts in combination with 
other gene polymorphisms such as the variants of CCR5, 
CXCR4, and possibly human leukocyte antigen (HLA) 
gene variants [51] in promoting or preventing infection. 
It has been suggested that activation of the immune 
system rather than receptor blockage explains the 
association with HIV/AIDS [47].
A variety of HLA gene variants are associated with 
susceptibility to HIV/AIDS in adults. Th  is  includes  HLA 
complex P5 (HCP5) rs2395029 (in strong linkage 
disequilibrium with HLA-B*5701) and HLA-C rs926942 
associated with HIV viral set point [52] in a genome-wide 
association study, HLA-Bw4 associated with a lower risk 
of heterosexual HIV transmission [53], and HLA-B*35 
alone [54,55] or in combination with HLA-Cw*04  [56] 
associated with disease progression. An epistatic 
interaction between HLA-B Bw4-80I and activating killer 
immunoglobulin-like receptors (KIR) variant KIR3DS1 
has also been associated with a protection from rapid 
progression to AIDS [57,58], likely through increases in 
natural killer cell activity, cell lysis, and subsequent 
reduc  tion in viral load [57].
More pertinent to HIV MTCT are HLA variants evalu-
ated in pregnant women or maternal-fetal poly  mor  phism 
mismatches in HLA variants, which can protect infants 
from infection. One study found that mothers with HLA-B 
variants (*1302, *3501, *3503, *4402, *5001) transmitted 
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whereas mothers with other variants (*4901, *5301) did 
not transmit the virus despite high viral loads [59]. 
Furthermore, mother-infant pairs discordant with regards 
to the HLA-G variants 3743C/T, 634C/G, or 714insG/G 
have been shown to experience a lower risk of HIV MTCT 
compared to concordant mother-child pairs [60].
Th  e MBL2 gene plays a role in the innate immune 
responses to infection and encodes the mannose-binding 
lectin (MBL) protein [61-64]. Several MBL2 poly  mor-
phisms can result in MBL deﬁ  ciency, which has been 
associated with increased risk of HIV MTCT [65]. 
Apolipoprotein B mRNA Editing Catalytic Polypeptide 
3g (APOBEC3G ), inhibits HIV-1 replication [66] and is 
associated with disease progression in children [67]. 
However, the association between APOBEC3G variants 
in the risk of HIV MTCT has not been established.
It is possible that the genetic risk factors involved in 
HIV infection and disease progression in adults do not 
directly overlap with the HIV MTCT phenotype and that 
the mechanisms with genetic underpinnings for HIV 
MTCT await discovery. It is also likely that what we know 
about HIV MTCT genetic risk factors is only one piece of 
the puzzle. To uncover new genes associated with HIV 
MTCT, we conducted a whole genome scan for fetal 
susceptibility to maternal HIV infection using infor-
mation from consenting mother-infant pairs receiving 
antenatal care in Blantyre, Malawi, a population with a 
high burden of HIV/AIDS.
Because HIV MTCT is a rare phenotype, it is diﬃ   cult 
to ascertain thousands of cases in order to obtain 
adequate power for a typical genome-wide association 
study. However, genome-wide approaches for such a 
pheno  type can still be fruitful for furthering our under-
standing of HIV MTCT etiology and for generating 
hypotheses. Where possible, we also report the eﬀ  ects of 
SNPs within genes known to be associated with HIV/
AIDS, for the purposes of replication in our study 
population.
Methods
Study design and population
Th  e study participants were a subset of a larger pros-
pective cohort study of malaria and HIV in pregnancy 
[68,69]. Th  e cohort was conducted from 2000 to 2004 
and included 3,825 consenting pregnant women admitted 
to Queen Elizabeth Central Hospital in Blantyre, Malawi, 
as previously described [69]. HIV-infected women and 
their infants received a single dose (200 mg) of NVP at 
the onset of labor or at the time of delivery, respectively. 
A total of 1,157 women tested positive for HIV, 884 of 
which delivered at Queen Elizabeth Central Hospital, 
resulting in 807 singleton live births. At delivery, 751 
infants were tested for HIV, identifying 65 HIV positive 
infants at birth. Of the 686 HIV negative infants, 179 
were lost to follow-up. Th   e remaining 507 HIV negative 
infants were tested for HIV at 6 and 12 weeks, resulting 
in 89 additional HIV positive infants. Based on mother 
reports, 98.4% and 96.5% of infants were breast fed at 6 
and 12 weeks postpartum, respectively.
In order to evaluate infant susceptibility to maternal 
HIV infection, a nested case control was conducted, 
focusing on infants of HIV positive mothers. Given that 
all such infants were HIV-exposed, cases were deﬁ  ned as 
infants who became HIV positive at birth, 6 weeks, or 
12 weeks. Controls were deﬁ  ned as infants who remained 
HIV negative at all visits. Genotyping was performed for 
as many cases as possible. We ﬁ  rst evaluated samples for 
suﬃ   cient DNA for genome-wide genotyping, which was 
obtainable for 115 of the 154 cases. Funding and supplies 
were only available to test an approximately 1:1 
case:control ratio. We selected controls in a slightly 
higher than 1:1 case:control ratio, anticipating loss of 
samples due to insuﬃ   cient DNA. A total of 203 of the 
418 controls were selected using simple random selection 
in STATA version 10 [70], 153 of which had suﬃ   cient 
DNA. Th   e controls had a similar distribution across time 
of enrollment as the cases. Th  e total sample size 
subjected to genotyping was 268 infants (115 cases + 153 
controls) of HIV positive mothers. Because the control 
status of subjects was designated at the beginning of 
sample selection for the nested case control, this study 
was analyzed as a case-cohort study [71]. Mothers of 
infants could not be genotyped as the original insti-
tutional review board approval did not include this. It 
was not possible to return to study participants in order 
to obtain informed consent for maternal genotyping. 
Th   us, no test of transmission disequilibrium or analyses 
involving mother-infant pairs could be conducted. Th  e 
focus was infant genomic susceptibility to HIV infection, 
given an HIV positive mother. Th   e original cohort study 
obtained consent from study participants to collect and 
use samples for biological measurements including but 
not limited to diagnosis of disease and for genotyping. 
Written informed consent forms were available in both 
English and Chichewa, the predominant language in 
Malawi. Th   is study was approved by the Malawi College 
of Medicine Research and Ethics Committee and by the 
institutional review board at the University of North 
Carolina at Chapel Hill. Modiﬁ   cation of the original 
institutional review board approval was obtained to 
ensure the approval of large-scale genotyping of SNPs 
across the genome.
Power analysis
Power was calculated based on a genome-wide scan of 
approximately 587,000 SNPs, as over 68,000 SNPs were 
removed due to quality control. Per speciﬁ  cations of the 
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additive model, varying allele frequency (10 to 30%), a 
baseline risk of 25% (to approximate the proportion of 
infants that became infected with HIV from HIV positive 
mothers in the genome wide association study popu  la-
tion), a case to control ratio of 1:1, and an Bonferroni 
adjusted  P-value of 0.05/600,000 SNPs = 1 × 10-8 to 
account for multiple testing. Power was estimated for 
varying relative risks (1.25 to 3.25).
Genotyping
Infant genotyping was performed at Duke University 
Genotyping Core Laboratories, by using Illumina’s 
HumanHap650Y Genotyping BeadChip. Th  is BeadChip 
enables whole-genome genotyping of over 655,000 
tagSNPs derived from the International HapMap Project 
[73] and over 100,000 tag SNPs selected based on the 
Yoruban Nigerian HapMap population. Th  e BeadChip 
contains over 4,300 SNPs with copy number poly-
morphism regions of the genome, 8,000 non-synonymous 
SNPs, 1,800 tag SNPs in the major histocompatibility 
complex important for immunological relevance, 177 
mitochondrial SNPs, and 11 Y-chromosome SNPs.
Quality control
Th   e quality control for genotyping error was performed 
at Duke University Genomic Laboratories as previously 
described [52]. Brieﬂ  y, all samples were brought into a 
BeadStudio data ﬁ   le and clustering of samples was 
evaluated in order to determine random clustering of 
SNPs. Samples with very low call rates (<95%) or insuf-
ﬁ   cient DNA concentration were excluded. Subsequent 
reclustering of undeleted SNPs and additional exclusion 
by call rate was performed [52]. SNPs with a Het Excess 
value between -1.0 to -0.1 and 0.1 to 1.0 were evaluated 
to determine if raw and normalized data indicated clean 
calls for the genotypes [52].
Statistical quality control was performed at the Univer  sity 
of North Carolina at Chapel Hill. Individuals missing more 
than 10% of marker data, SNPs missing more than 10% of 
genotypes, SNPs with a minor allele frequency (MAF) 
≤0.01, and SNPs out of Hardy-Weinberg equilibrium 
(HWE) (P < 0.001) in the control group were excluded. 
Gender veriﬁ  cation was completed for all subjects to ensure 
that gender recorded in the covariate dataset matched with 
gender based on genetic data. For mismatched or missing 
gender, gender was imputed based on the X chromosome 
(N = 9). Related individuals were identiﬁ  ed by ﬁ  rst esti-
mating identity by descent (IBD). A minimal list of 
individuals with estimated genome-wide IBD proportions 
>  0.05 with at least one included subject were removed 
(N = 5). Statistical quality control was performed in PLINK 
version 1.05 [74]. Analyses were run without exclusions due 
to HWE in order to assess the diﬀ  erence in results.
Statistical analysis
Assuming an additive genetic model, logistic regression 
was performed where the outcome of interest was HIV 
status of the infant (positive or negative). Th   e null hypo-
thesis was that the SNP of interest was not associated 
with HIV MTCT: Ho: β1 = 0, compared to the alternative 
hypothesis, that the SNP was associated with HIV MTCT: 
Ha: β1 ≠ 0. All SNPs were assumed to be independent, and 
Bonferroni correction was used to adjust for multiple 
testing. Odds ratios (ORs) were obtained to approximate 
the risk ratios. Th   ese statistical analyses were conducted in 
PLINK version 1.05 [74] and the results were visualized in 
WGAViewer version 1.26F [75].
Logistic regression was adjusted for maternal viral load 
(MVL), as it is a key risk factor for HIV MTCT. MVL 
could not be evaluated for eﬀ  ect measure modiﬁ  cation 
because of the small sample size. Logistic regression 
results were presented for both unadjusted and MVL 
adjusted analyses. We also investigated maternal syphilis 
for signiﬁ   cant confounding, although the number of 
infants of HIV positive mothers who also had syphilis 
was small (N = 20). We did not evaluate maternal malaria 
for confounding as it was not associated with the 
outcome, HIV MTCT [68,69]. In order to evaluate 
population stratiﬁ  cation, principal components analysis 
was performed by using EIGENSOFT version 2.0 [76,77]. 
Principal component(s) (PCs) were then evaluated for 
association for SNPs associated with HIV MTCT. PCs 
were determined to represent potential confounders if 
they were associated with both the SNP of interest and 
HIV MTCT. If necessary, logistic regression was repeated 
adjusting for confounding PCs.
In order to evaluate the consistency of associations by 
mode of transmission, we evaluated each SNP for asso-
ciation with intrauterine and intrapartum trans  mission. 
Intrauterine transmission was estimated by infant HIV 
status at birth. Intrapartum transmission was assigned to 
infants who were HIV negative at birth but who became 
HIV positive at week 6. Transmission through breast-
feeding was estimated at week 12. For each mode of 
transmission, the results for SNPs within key genes 
previously associated with HIV/AIDS were summarized.
Results
Quality control and power analysis
    A total of 246 infants (114 cases, 132 controls; 116 males, 
121 females, 9 with imputed gender) passed laboratory 
quality control. Statistical quality control removed 15 
individuals for low genotyping and 5 who had estimated 
genome-wide IBD proportions > 0.05 with at least one 
included subject. Th   is resulted in a total of 226 
individuals (100 cases, 126 controls; 112 males, 114 
females). Of the 655,352 SNPs tested, 68,671 failed 
statistical quality control due to HWE P < 0.001 in the 
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for MAF <0.01 (N = 53,477), where some overlap of SNPs 
across exclusion criteria existed. Results are summarized 
for 586,681 SNPs.
No evidence of population stratiﬁ  cation was present 
(Eigen value range: 0.817 to 1.20, mean = 0.995, genomic 
inﬂ  ation factor based on median χ2 = 1.023, mean χ2 = 
1.013). Th   e power analyses estimated that with a P-value 
of 1 × 10-8, a baseline risk of 25%, and an allele frequency 
of 10%, our power was ≤32% and 58% for a relative risk 
(RR) of ≤3.0 and 3.5, respectively. For an allele frequency 
of 20%, this changed to 10%, 50%, 85%, and 97%, for RR = 
2.0, 2.5, 3.0, and 3.5, respectively. And for an allele 
frequency of 30%, this changed to 22%, 75%, 96%, and 
99%, for RR = 2.0, 2.5, 3.0, and 3.5, respectively. Th  is 
implies that our genome-wide association dataset with a 
sample size of 226 is powered to detect large eﬀ  ects of 
very common variants, but underpowered to detect small 
eﬀ  ects of rare variants. Because additional cases could 
not be obtained, we were unable to increase sample size 
in order to boost power. Rather, limited genome-wide 
statistical signiﬁ  cance was noted.
Association results
Although no genome-wide signiﬁ  cant SNPs were detected 
(P < 1 × 10-7), we identiﬁ  ed nine SNPs within six genes 
with a P-value <5 × 10-5 in either unadjusted analyses 
and/or analyses adjusted by MVL (Table 1). Adjustment 
by maternal syphilis made little impact on the eﬀ  ect 
estimates or statistical signiﬁ   cance (data not shown). 
Several of the 50 most signiﬁ   cant SNPs were located 
within interesting genes, including 7 SNPs near or within 
genes involved in pregnancy and development (Table 2). 
An additional 7 SNPs were located near or within genes 
with immunological function and/or HIV-1 protein 
interactions (Table 3). One of the top SNPs corresponding 
to functional interest was rs8069770, located within the 
gene heparan sulfate (glucosamine) 3-O-sulfotransferase 
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Table 1. HIV MTCT association results for SNPs, selected by P-value
        Unadjusted    Adjusted  OR   
CHR SNPtype  A1  A2  MAF  OR (95% CI)  P  (95% CI)  P  Nearest gene
17 rs12306a  A  G  0.23  0.33 (0.20, 0.55)  2.02E-05  0.34 (0.20, 0.57)  3.92E-05  WD repeat and SOCS box-containing 1 (WSB1)
8 rs476321a  T  C  0.27  2.55 (1.65, 3.92)  2.15E-05  2.50 (1.62, 3.87)  3.42E-05  Protein coding, protein info: transcription factor 
                  CP2-like 3, deafness, autosomal dominant 28, 
                  grainyhead-like 2 (Drosophila) (GRHL2)
6 rs2268993a  C  G  0.27  2.71 (1.71, 4.28)  2.20E-05  2.70 (1.70, 4.28)  2.65E-05  Solute carrier family 35 (CMP-sialic acid transporter), 
                member  A1  (SLC35A1)
18 rs8084223b  T  C  0.15  0.26 (0.14, 0.49)  3.41E-05  0.26 (0.14, 0.50)  4.21E-05  AC104961.7
23 rs5934013a  G  A  0.15  4.18 (2.12, 8.24)  3.61E-05  4.09 (2.08, 8.06)  4.68E-05  FERM and PDZ domain containing 4 (FRMPD4)
8 rs9314565b  G  C  0.47  0.42 (0.27, 0.63)  4.13E-05  0.41 (0.27, 0.63)  3.64E-05  AC019176.4
3 rs4234621b  C  T  0.28  0.39 (0.25, 0.61)  5.03E-05  0.38 (0.24, 0.60)  4.58E-05  Pyrin domain containing 2 (PYDC2)
14 rs2287652a  C  A  0.2  0.32 (0.19, 0.56)  5.15E-05  0.33 (0.19, 0.57)  7.12E-05  aarF domain containing kinase 1 (ADCK1)
9 rs1889055b  C  N/A  0.24  2.52 (1.61, 3.93)  5.21E-05  2.48 (1.59, 3.87)  6.32E-05  RP11-48L13.1
7 rs216743a  A  G  0.1  4.22 (2.09, 8.53)  6.16E-05  4.23 (2.08, 8.61)  6.89E-05  cAMP responsive element binding protein 5 (CREB5)
7 rs216744a  G  G  0.1  4.22 (2.09, 8.53)  6.16E-05  4.23 (2.08, 8.61)  6.89E-05  cAMP responsive element binding protein 5 (CREB5)
22 rs131817a  T  G  0.23  0.37 (0.22, 0.60)  6.68E-05  0.36 (0.22, 0.59)  6.62E-05  Non-SMC condensin II complex, subunit H2 
                ( NCAPH2)
7 rs4722999a  C  C  0.32  2.46 (1.58, 3.84)  7.07E-05  2.38 (1.52, 3.72)  1.49E-04  Corticotropin releasing hormone receptor 2 (CRHR2)
17 rs8069770a  T  G  0.14  0.27 (0.14, 0.51)  7.17E-05  0.25 (0.13, 0.49)  3.79E-05  Heparan sulfate (glucosamine) 3-O-sulfotransferase 
                3A1  (HS3ST3A1)
5 rs6884962c  G  A  0.49  2.18 (1.48, 3.21)  7.31E-05  2.15 (1.46, 3.17)  1.07E-04  AC008412.8
12 rs12579934a  T  A  0.46  2.24 (1.49, 3.36)  9.59E-05  2.48 (1.63, 3.78)  2.45E-05  Branched chain aminotransferase 1, cytosolic (BCAT1)
9 rs12376718b  T  A  0.15  3.07 (1.75, 5.39)  9.79E-05  2.97 (1.69, 5.20)  1.47E-04  RP11-48L13.1
16 rs6540013b  G  C  0.39  0.45 (0.30, 0.68)  1.16E-04  0.44 (0.29, 0.66)  8.99E-05  AC010531.8
16 rs12598821a  T  T  0.48  0.45 (0.30, 0.68)  1.20E-04  0.43 (0.28, 0.65)  6.65E-05  AC010333.7
1 rs3861824b  A  G  0.11  0.23 (0.11, 0.50)  1.98E-04  0.20 (0.09, 0.44)  6.29E-05  Disabled homolog 1 (Drosophila) (DAB1)
Top 20 most signifi  cant SNPs based on P-values from crude and/or adjusted by maternal HIV viral load analyses, sorted by unadjusted P-value. CHR, chromosome; 
SNPtype, SNP and type, where type refers to the position of the SNP relative to the closest gene (aintronic, bintergenic, cupstream); A1, risk allele designated by PLINK; 
A2, major allele; MAF, minor allele frequency; OR, odds ratio; 95% CI, 95% confi  dence interval of the OR; Adjusted OR, OR from analyses adjusted by maternal HIV viral 
load.3A1 (HS3ST3A1; Figure 1). Analyses run including SNPs 
out of HWE in the control group gave similar results 
(data not shown). None of the ten PCs evaluated were 
associated with rs8069770 (P = 0.763, 0.977, 0.715, 0.447, 
0.320, 0.714, 0.523, 0.958, 0.696, 0.902). Th  us,  subsequent 
adjustment by PCs was not necessary.
For the top 20 most signiﬁ  cant SNPs summarized in 
Table 1, we evaluated the eﬀ  ect estimates and statistical 
signiﬁ  cance for intrauterine and intrapartum HIV trans-
mission (Additional ﬁ  le 1). We were unable to include 
results for transmission through breastfeeding because 
the outcome was too rare. For all SNPs described, the 
direction of eﬀ   ect (higher risk or lower risk of HIV 
transmission) was consistent across mode of transmission 
(Additional ﬁ  le 1). Th   e results for SNPs within 10 kb of 
key genes of interest were also reported (Additional ﬁ  le 2). 
We were unable to report results speciﬁ  c to the marker 
for the CCL3L1 copy number variation, rs72248989, but 
we report the eﬀ  ects of SNPs in this region (Additional 
ﬁ  le 2).
Discussion
We conducted a genome-wide association study to 
identify genetic variants that may inﬂ  uence HIV MTCT. 
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Table 2. Top SNPs in or near genes with roles in pregnancy and development
CHR SNPtype  P  Nearest gene  Presumed gene function
17 rs8069770a  3.79E-05  Heparan sulfate (glucosamine)   Abundant expression in placenta; HIV-1 requires the gene product heparan sulfate
      3-O-sulfotransferase 3A1 (HS3ST3A1)  proteoglycans for uptake in trophoblasts (cells forming the placental barrier); 
        involved in biosynthesis of an entry receptor for herpes simplex virus 1
17 rs12306a  3.92E-05  WD repeat and SOCS   Unknown protein function induced by Hedgehog signaling in embryonic structures
      box-containing 1 (WSB1)  during chicken development
4 rs1433666a  1.00E-04  Glutamate receptor, ionotropic,   Homozygosity for this mutation in mice results in death shortly after birth, related to
      delta 2 (GRID2)  the loss of mid- and hindbrain neurons during late embryogenesis
5 rs6884962b  1.00E-04  NK2 transcription factor related,   Regulates tissue-specifi  c gene expression essential for tissue diff  erentiation; 
      locus 5 (Drosophila) (NKX2-5)  regulates temporal and spatial patterns of development
7 rs4722999a  1.00E-04  Corticotropin releasing hormone   Detected in placenta, myometrium, decidua, and fetal membranes; expression is
      receptor 2 (CRHR2)  down-regulated in uterine tissues during pregnancy, most pronounced in laboring 
        cervix; suggested paracrine role in birth process (for example, eff  ects on 
        macrophages and endothelial cells)
2 rs2677510b  3.00E-04  GLI-Kruppel family member   Role during embryogenesis, DNA binding, and Sonic hedgehog (Shh) signaling to
     GLI2  (GLI2)  oncogenes in embryonal carcinoma cells
6 rs2268447a  4.00E-04  Pleiomorphic adenoma   Mutations associated with congenital abnormalities, potential role in ovarian and
      gene-like 1 (PLAGL1)  other types of cancer; genetically imprinted in neonatal diabetes
The sources of the presumed gene function are NCBI Entrez Gene and OMIM [88,94]. CHR, chromosome; SNPtype, SNP and type, where type refers to the position of the 
SNP relative to the closest gene (aintronic, bintergenic); P, adjusted by maternal HIV viral load P-value.
Table 3. Top SNPs in or near genes with immunological function or HIV-1 protein interactions
CHR SNPtype  P  Nearest gene  Presumed gene function
6 rs3131036a  2.00E-04  Discoidin domain receptor family,   Proximal to HLA genes; interacts w/collagen to up-regulate IL-8 and infl  ammatory
      member 1 (DDR1) macrophages.
10 rs3124199b  2.00E-04  Mitogen-activated protein kinase   Promotes production of TNF-alpha and IL-2 during T lymphocyte activation; 
      kinase kinase 8 (MAP3K8)  promotes proteolysis of cytokine activator NFKB1 in rats.
4 rs1358594b  3.00E-04  Interleukin 8 (IL8)  HIV-1 Nef, Tat, and Vpr regulate IL-8 expression. IL-8 protein mediates infl  ammatory 
        response including CD4+ response to HIV-1 infection.
7 rs10254544c  3.00E-04  Nucleoporin like 2 (NUPL2)  Interacts with HIV-1 Rev to mediate nuclear import of viral DNA and inhibit nuclear 
        export of HIV-1 mRNA.
9 rs302923d  3.00E-04  General transcription factor IIIC,   HIV-1 Tat upregulates RNA polymerase III transcription by activating this gene.
      polypeptide 4, 90kDa (GTF3C4)
20 rs6037908b  3.00E-04  Prion protein (p27-30) (Creutzfeldt-  HIV-1 Tat binds to a stem-loop structure in the mRNA of PrP, upregulating
      Jakob disease, Gerstmann-Strausler-  expression.
      Scheinker syndrome, fatal familial
     insomnia)  (PRNP)
7 rs6951646b  4.00E-04  Sp4 transcription factor (SP4)  Activates the HIV-1 LTR promoter, possibly enhancing HIV-1 Tat-mediated 
        transactivation of the viral promoter.
The sources of the presumed gene function are NCBI Entrez Gene and OMIM [88,94]. CHR, chromosome; SNPtype, SNP and type, where type refers to the position of the 
SNP relative to the closest gene (aintronic, bintergenic, cupstream, ddownstream); P, adjusted by maternal HIV viral load P-value.Although limited by sample size and the power to detect 
genome-wide statistical signiﬁ  cance, we were powered to 
detect large genetic eﬀ  ects for common variants (eﬀ  ect 
estimate >3.0, MAF >20% or eﬀ  ect estimate >2.5, allele 
frequency >25%). No such genome-wide statistically 
signiﬁ   cant genetic eﬀ   ects were detected. Nonetheless, 
several ﬁ  ndings were notable and may oﬀ  er supportive 
data for other studies of the genetics of HIV MTCT.
Several SNPs with biological signiﬁ  cance were noted. 
One of these is the SNP rs8069770, located within the 
gene  HS3ST3A1. Th  is gene encodes the enzyme 3-O-
sulfotransferase, which catalyzes the biosynthesis of a 
speciﬁ   c subtype of heparan sulfate (HS), 3-O-sulfated 
heparan sulfate. Th   is HS subtype has speciﬁ  c functional 
signiﬁ  cance for herpes simplex virus-1 [78,79]. Although 
HS has been shown to be involved in HIV infection 
[80-83], to our knowledge, no sub-type-speciﬁ  c investi-
ga  tions of HS have been conducted for association with 
HIV MTCT. Furthermore, HIV-1 virus [41,84] and the 
chemo  kine RANTES [41,85,86] have been noted to bind 
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Figure 1. Map of the HS3ST3A1 gene on chromosome 17. Position and -log(p) of SNPs in the region are displayed, including the SNP rs8069770 
with the highest -log(p). Triangle display of linkage disequilibrium across SNPs corresponds to r2 estimates. Plot constructed using WGAViewer 
software version 1.26F.
rs8069770to syndecans, which are core transmembrane proteins 
capable of carrying HS [87]. It is possible that speciﬁ  c or 
multiple components of HS proteoglycans, which consist 
of the bound core protein attached to HS, are involved in 
HIV MTCT. We suggest two possible mechanisms: the 
attachment of HS proteoglycans to HIV could prevent 
the virus from crossing the placenta and possibly facili-
tate viral sequestration in the placenta; or, HS 
proteoglycans binding with RANTES could leave CCR5 
receptors available to bind with HIV virus and facilitate 
transmission across the placenta. Th   e former mechanism 
would agree with the direction of eﬀ  ect we observed for 
rs8069770. However, much more research is needed in 
order to more clearly develop mechanistic hypotheses 
involving HS, at both the genetic level regulating the 
biosynthesis of HS subtypes, and at the protein level. We 
observed that the frequency of the minor allele of 
rs8069770 among cases/controls was similar across 
transmission type: case/control frequencies were 
0.07/0.19, 0.07/0.16, and 0.09/0.18 for cumulative HIV 
MTCT, intrauterine transmission, and intrapartum trans-
mission, respectively. Th  e direction of eﬀ   ect was also 
consis  tent across transmission category (Additional ﬁ  le 1), 
suggesting that the mechanism may not be speciﬁ  cally 
localized to the placenta.
Two SNPs were located within genes involved in 
embry  onic development in animal models [88]: rs12306 
(P = 3.29 × 10-5) within the WD repeats and SOCS box-
containing 1 (WSB1) gene, and rs1433666 (P = 0.0001) 
within the Glutamate receptor, ionotropic, delta 2 
(GRID2) gene. Th  e role of WSB1 in human embryonic 
development or in the risk of HIV MTCT is not well 
described.  GRID2  has been noted as a large region of 
genomic instability (fragile site) and has been associated 
with cancer and neural development [89,90]. Subsequent 
studies of these genes in humans would be valuable, in 
particular for probing roles in viral infection.
Th   ere were two SNPs (rs216743 and rs216744) with P-
values <7 × 10-5 identiﬁ   ed in the cAMP response 
element binding protein 5 gene (CREB5). Th  e CREB5 
product is part of the CRE (cAMP response element)-
binding protein family. One member of this family, 
CRE-BP1, is involved in mediating the adenovirus E1A-
induced trans-activation [91]. CREB5 has also been 
noted to serve as an integration site for xenotropic 
murine leukemia virus-related virus (XMRV) in prostate 
cancer tissue from patients homozygous for a reduced 
activity variant of the antiviral enzyme RNase L [92]. 
Another SNP, rs1358594 (P = 0.0003), was of interest as 
it is within IL8, which mediates inﬂ  ammatory response 
to HIV-1 infection [88]. Six other SNPs were found 
within genes that play a role in HIV infection. Th  is  may 
be suggestive of similar roles for such genes in HIV 
MTCT.
Th  e Illumina 650Y BeadChip methodology provides 
genotypes of predominantly biallelic SNPs that are 
approximately evenly spaced across the genome rather 
than selected based on known functional signiﬁ  cance. 
Th   is limited our ability to replicate associations between 
some regions of interest (that is, CCR5) and HIV MTCT 
in this study. We were also unable to directly evaluate 
some key copy number variations (that is, CCL3L1) for 
association with HIV MTCT. However, we do describe 
the results for SNPs within 10 kb of the key genes 
associated with HIV/AIDS, including the association 
between SNPs close to the marker for the CCL3L1 copy 
number variation rs71148989 (Additional ﬁ   le 2). Our 
small sample size may also have limited our ability to 
detect statistically signiﬁ   cant associations in some 
regions of interest, in particular for small eﬀ  ects.
We did not describe the most statistically signiﬁ  cant 
SNPs (potentially diﬀ  erent sets of top SNPs) by mode of 
transmission because of the small number of cases by 
transmission type. Rather, we compare the results for top 
SNPs from cumulative HIV MTCT analyses across other 
modes of transmission (intrauterine/intrapartum; Addi-
tional ﬁ  le 1) to assess consistency. Because the number of 
transmission events through breastfeeding was very rare 
(N = 10), we were unable to report the associations speciﬁ  c 
to postpartum transmission. We observed consistent 
direction of eﬀ  ects (higher/lower risk of HIV MTCT) 
across mode of transmission, which suggests that the 
eﬀ   ects of the top SNPs are not speciﬁ   c to biological 
events taking place in utero. However, for some SNPs, the 
strength of eﬀ  ect diﬀ  ered across transmission type. For 
example, rs5934013 of FERM and PDZ domain 
containing 4 (FRMPD4) was associated with a higher risk 
of HIV MTCT (MVL-adjusted OR = 4.09, 95% conﬁ  dence 
interval (CI) = 2.08, 8.06), also found for intrauterine 
transmission (MVL-adjusted OR = 1.83, 95% CI = 0.96, 
3.47), and intrapartum transmission (MVL-adjusted 
OR = 3.39, 95% CI = 1.46, 7.85). Th   e stronger eﬀ  ect size 
for intrapartum compared to intrauterine transmission is 
interesting, possibly useful for developing mechanistic 
hypotheses, but warrants caution with interpretation due 
to sample size.
We previously noted that all mothers in the study 
received NVP, in accordance with the HIVNET 012 
protocol [93]. Th  is may limit the generalizability of our 
ﬁ  ndings to populations with diﬀ  erent drug treatment or 
with no drug treatment during pregnancy or after 
delivery. It may also have limited our ability to replicate 
or identify novel SNP associations with HIV MTCT that 
are only present in the absence of treatment. However, 
because NVP treatment was administered to all subjects, 
this study may more clearly illustrate the genetic eﬀ  ects 
that are strong enough to maintain association with HIV 
MTCT even in the context of NVP. Such eﬀ  ects may be 
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pharmacogenomic research eﬀ  orts.
Due to the nature and frequency of this rare HIV 
MTCT phenotype, we were unable to ascertain a suﬃ   -
cient number of cases to be powered to establish 
genome-wide statistical signiﬁ  cance. However, this study 
did provide some new insights into the genetics of HIV 
MTCT and aims to facilitate future genetic studies for 
this phenotype.
Conclusions
Th  is study evaluated over 586,000 SNPs for association 
with HIV MTCT in a set of HIV-exposed infants from 
Blantyre, Malawi. Although we were unable to detect 
genome-wide statistically signiﬁ  cant eﬀ  ects, several SNPs 
with P-values <5 × 10-5 with biological signiﬁ  cance were 
noted. Replication of this work using a larger sample size 
will help us to diﬀ  erentiate true positive ﬁ  ndings.
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